Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial. uri icon

authors

  • Michael Nanna, MD, MHS
  • Toliver, Joshua C
  • Doan, Quan V
  • Fabricatore, Anthony
  • Faurby, Mads
  • Henry, Alasdair D
  • Houshmand-Oeregaard, Azadeh
  • Levine, Alina
  • Navar, Ann Marie
  • Scassellati Sforzolini, Thomas

publication date

  • April 4, 2025